{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-003063","form_type":"8-K","ticker":"CNSP","cik":"0001729427","company_name":"CNS Pharmaceuticals, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.777225+00:00","generated_at":"2026-06-02T19:17:03.170522+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nasdaq Panel grants CNS Pharmaceuticals extension to July 15, 2024 to regain listing compliance","bullets":["Hearing held April 18, 2024; panel grants extension until July 15, 2024.","Must demonstrate compliance with minimum bid price (Rule 5550(a)(2)) and stockholders' equity (Rule 5550(b)).","Company intends to implement its plan to meet the milestones set by the Panel.","Failure to comply by July 15 could result in delisting from Nasdaq."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-003063","json":"https://secwatch.observer/filing/0001683168-24-003063.json","markdown":"https://secwatch.observer/filing/0001683168-24-003063.md","text":"https://secwatch.observer/filing/0001683168-24-003063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824003063/0001683168-24-003063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824003063/cns_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T19:17:03.170522+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}